Get the Stockscreener App
0.2927
1.14%
0.0022
IGC Pharma Inc stock is traded at $0.2927, with a volume of 67,127.
It is up +1.14% in the last 24 hours and down -2.03% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.2905
Open:
$0.2943
24h Volume:
67,127
Relative Volume:
0.09
Market Cap:
$27.74M
Revenue:
$1.22M
Net Income/Loss:
$-14.15M
P/E Ratio:
-1.1258
EPS:
-0.26
Net Cash Flow:
$-6.55M
1W Performance:
+4.89%
1M Performance:
-2.03%
6M Performance:
-19.77%
1Y Performance:
-10.15%
1-Day Range:
$0.2914
$0.2954
1-Week Range:
$0.28
$0.31
52-Week Range:
$0.2525
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.2919 | 27.61M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.56 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.32 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
868.54 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
361.68 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.25 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
IGC Pharma Inc Stock (IGC) Latest News
Aug Volume: Should I buy SONY stock nowEarnings Growth Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
IGC Pharma announces registered direct equity offering financing - MSN
IGC Pharma Expands Phase 2 CALMA Trial With New Clinical Trial Site at Integrative Clinical Trials in New York - 富途资讯
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York - Finviz
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial S - GuruFocus
IGC Expands Alzheimer's Clinical Trial with New Site in Brooklyn - GuruFocus
NYC clinic joins trial of cannabinoid drug for Alzheimer's agitation - Stock Titan
Retail Trends: Whats the MACD signal for Invesco QQQ Trust Series 12025 Market Outlook & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Performance Recap: Is IGC Pharma Inc a cyclical or defensive stockJuly 2025 Update & Real-Time Market Trend Scan - baoquankhu1.vn
Does IGC Pharma Inc stock have upside surprise potentialMarket Risk Summary & Technical Pattern Alert System - baoquankhu1.vn
Weekly Recap: Is IGC Pharma Inc likely to announce a buybackExit Point & Fast Entry High Yield Tips - baoquankhu1.vn
Loss Report: Can IGC Pharma Inc deliver alphaJuly 2025 Retail & AI Enhanced Execution Alerts - baoquankhu1.vn
IGC Pharma expands Phase 2 CALMA trial with new clinical site - TipRanks
IGC Pharma Expands Alzheimer's Clinical Trial with New Research Site - GuruFocus
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia - ACCESS Newswire
Whittier Daily News - FinancialContent
Published on: 2026-01-11 01:25:41 - Улправда
IGC Pharma adjusts fiscal year-end to December 31 - MSN
Can IGC Pharma Inc. stock outperform in 2025 bull marketTrade Risk Summary & Capital Protection Trading Alerts - ulpravda.ru
Why IGC Pharma Inc. stock gets analyst attentionQuarterly Performance Summary & Consistent Return Strategy Ideas - Улправда
Will IGC Pharma Inc. stock deliver long term returnsJuly 2025 Selloffs & Advanced Swing Trade Entry Alerts - Улправда
Can IGC Pharma Inc. stock sustain revenue momentum2025 Investor Takeaways & Low Volatility Stock Suggestions - ulpravda.ru
How IGC Pharma Inc. stock reacts to inflationary pressuresMarket Movers & Fast Momentum Entry Tips - ulpravda.ru
Is IGC Pharma Inc. stock attractive after correctionProfit Target & Low Risk High Reward Trade Ideas - Улправда
Does IGC Pharma Inc. (IGS1) stock trade below intrinsic value2025 Market WrapUp & Weekly Breakout Opportunity Watchlist - ulpravda.ru
Will IGC Pharma Inc. stock outperform Dow Jones indexJuly 2025 EndofMonth & High Win Rate Trade Alerts - Улправда
How IGC Pharma Inc. stock benefits from strong dollarSell Signal & Consistent Profit Trade Alerts - ulpravda.ru
Can IGC Pharma Inc. stock double in next 5 yearsWeekly Volume Report & Weekly Top Performers Watchlists - ulpravda.ru
How dovish Fed policy supports IGC Pharma Inc. (IGS1) stockMarket Risk Analysis & Technical Buy Zone Confirmation - Улправда
Can IGC Pharma Inc. (IGS1) stock sustain institutional flowsCandlestick Pattern Analysis & Smart Trading Plans for Every Investor Type - bollywoodhelpline.com
IGC Pharma (IGC) Aligns Fiscal Year with Calendar Year - GuruFocus
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability - Finviz
IGC Pharma (NYSE American: IGC) prices direct 779,997-share stock sale - Stock Titan
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - Newswire.com
IGC Pharma Announces Registered Direct Equity Offering Financing - TipRanks
IGC Pharma Signs Subscription Agreement With Certain Investors - TradingView — Track All Markets
How IGC Pharma Inc. (IGS1) stock expands through international marketsAutomated Trading Signals & Low Cost Capital Gains - ulpravda.ru
This drug developer is switching its fiscal year to match your calendar - Stock Titan
IGC Pharma raises capital to advance IGC-AD1 Phase 2 trial - MSN
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial - BioSpace
IGC Pharma (NYSE American: IGC) plans $234K registered stock sale - Stock Titan
IGC Pharma (IGC) Secures Funding Through Share Sale - GuruFocus
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates - MSN
IGC Pharma Adjusts Fiscal Year-End to December 31 - TipRanks
IGC Pharma (IGC) shifts fiscal year-end to December 31 with 9‑month transition - Stock Titan
IGC Pharma, Inc. Approves Change in the Fiscal Year-End from March 31 to December 31 - marketscreener.com
IGC Pharma increases authorized shares to 600 million - MSN
Operating cash flow per share of IGC Pharma, Inc. – SWB:IGS1 - TradingView — Track All Markets
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.34%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):